Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tedopi + docetaxel
- Development stage
- Unknown
- Lead developer
- OSE Immunotherapeutics
- Modality
- Vaccines & Immunotherapeutics, Small Molecules, Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
Tedopi + docetaxel is an investigational combination therapy consisting of Tedopi (OSE-2101), an off-the-shelf neoepitope-based therapeutic cancer vaccine, and docetaxel, a microtubule-stabilizing taxane chemotherapy. Tedopi is designed to stimulate a cytotoxic T-lymphocyte (CTL) response against five tumor-associated antigens (TAAs) frequently overexpressed in non-small cell lung cancer (NSCLC): CEA, HER2, MAGE-2, MAGE-3, and p53. Docetaxel acts by binding to and stabilizing tubulin, preventing microtubule depolymerization and leading to cell cycle arrest and apoptosis. The combination is being evaluated as a second-line treatment for HLA-A2-positive patients with metastatic NSCLC who have progressed after first-line chemo-immunotherapy. In the Phase 2 Combi-TED trial, the combination demonstrated promising efficacy, meeting its primary endpoint of 1-year overall survival.
- Other names
- OSE-2101 + TaxotereOSE-2101 + docetaxelOSE2101 + TaxotereOSE2101 + docetaxelTedopi + TaxotereTedopi + docetaxeldocetaxel + OSE-2101docetaxel + OSE2101docetaxel + Tedopi
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)HLA-DR (Human leukocyte antigen DR)HLA-A (HLA class I histocompatibility antigen A alpha chain)MAGEA2 (Melanoma-associated antigen 2)MAGEA3 (Melanoma-associated antigen 3)γδ TCR (T-cell receptor)TP53 (Cellular Tumor Antigen p53 R175H)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)MHC II (Major histocompatibility complex class II receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Tedopi + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tedopi + docetaxel.